X4 Pharmaceuticals (XFOR) Amortization of Deferred Charges (2017 - 2025)
X4 Pharmaceuticals (XFOR) posted Amortization of Deferred Charges of $207000.0 for Q4 2025, down 6.33% on a QoQ basis from $221000.0 in Q3 2025, and up 2.99% year-over-year from $201000.0 in Q4 2024.
X4 Pharmaceuticals (XFOR) Amortization of Deferred Charges (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals' Amortization of Deferred Charges history runs 9 years deep, the most recent figure standing at $207000.0 for Q4 2025.
- Quarterly Amortization of Deferred Charges rose 2.99% year-over-year to $207000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $865000.0 (up 1.05% YoY) and the FY2025 annual result came in at $865000.0, up 1.05% from the prior year.
- Amortization of Deferred Charges was $207000.0 for Q4 2025 at X4 Pharmaceuticals, down from $221000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $265000.0 in Q4 2022 and bottomed at $178000.0 in Q1 2021.
- A 5-year average of $216200.0 and a median of $209500.0 in 2024 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2021 — Amortization of Deferred Charges jumped 49.58% — and 2024, when it declined 20.16%.
- X4 Pharmaceuticals' Amortization of Deferred Charges stood at $199000.0 in 2021, then soared by 33.17% to $265000.0 in 2022, then decreased by 6.42% to $248000.0 in 2023, then declined by 18.95% to $201000.0 in 2024, then gained by 2.99% to $207000.0 in 2025.
- Business Quant data shows XFOR's Amortization of Deferred Charges at $207000.0 in Q4 2025, $221000.0 in Q3 2025, and $212000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - |
| 4 | BeOne Medicines | 472.68 Bn | 467.89 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.24 Bn | 114.99 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.33 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - |
| 8 | Argenx Se | 55.93 Bn | 50.75 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.59 Bn | 34.58 Bn | 959.66 Mn |
| 10 | X4 Pharmaceuticals | 165.58 Mn | -51.47 Mn | 2.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 207,000.00 |
| Dec 31, 2025 | 207,000.00 |
| Sep 30, 2025 | 221,000.00 |
| Sep 30, 2025 | 221,000.00 |
| Jun 30, 2025 | 212,000.00 |
| Jun 30, 2025 | 212,000.00 |
| Mar 31, 2025 | 225,000.00 |
| Mar 31, 2025 | 225,000.00 |
| Dec 31, 2024 | 201,000.00 |
| Dec 31, 2024 | 201,000.00 |
| Sep 30, 2024 | 194,000.00 |
| Sep 30, 2024 | 194,000.00 |
| Jun 30, 2024 | 207,000.00 |
| Jun 30, 2024 | 207,000.00 |
| Mar 31, 2024 | 254,000.00 |
| Mar 31, 2024 | 254,000.00 |
| Dec 31, 2023 | 248,000.00 |
| Dec 31, 2023 | 248,000.00 |
| Sep 30, 2023 | 243,000.00 |
| Sep 30, 2023 | 243,000.00 |